LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

Начало・Списък с акции・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

4.66 7.13

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.33

Максимум

4.66

Ключови измерители
By Trading Economics
Приходи	9.6M -162M
Продажби	-14M 5.2M
EPS	-0.36
Марж на печалбата	-3,135.324
Служители	800
EBITDA	6.4M -141M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+83.49% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-102M 2.3B
Предишно отваряне	-2.47
Предишно затваряне	4.66

Настроения в новините

By Acuity

50%

167 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

4.15 / 4.75 Подкрепа & съпротива

Recursion Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.12.2025 г., 23:21 ч. UTC

Печалби

Придобивния, сливания и поглъщания

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3.12.2025 г., 23:14 ч. UTC

Придобивния, сливания и поглъщания

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3.12.2025 г., 22:01 ч. UTC

Значими двигатели на пазара

Costco Wholesale Reports Higher Monthly Sales

3.12.2025 г., 21:38 ч. UTC

Печалби

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3.12.2025 г., 23:59 ч. UTC

Пазарно говорене

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3.12.2025 г., 23:49 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.12.2025 г., 23:49 ч. UTC

Пазарно говорене

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3.12.2025 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3.12.2025 г., 23:13 ч. UTC

Пазарно говорене

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3.12.2025 г., 23:10 ч. UTC

Печалби

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3.12.2025 г., 23:08 ч. UTC

Пазарно говорене

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3.12.2025 г., 23:06 ч. UTC

Придобивния, сливания и поглъщания

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3.12.2025 г., 22:59 ч. UTC

Придобивния, сливания и поглъщания

EQB to Buy PC Financial From Loblaw for About $573.5M

3.12.2025 г., 22:45 ч. UTC

Пазарно говорене

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3.12.2025 г., 22:20 ч. UTC

Печалби

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3.12.2025 г., 22:19 ч. UTC

Печалби

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3.12.2025 г., 22:17 ч. UTC

Печалби

Salesforce Working to Add Voice to Agentforce, CEO Says

3.12.2025 г., 22:16 ч. UTC

Печалби

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3.12.2025 г., 22:15 ч. UTC

Печалби

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3.12.2025 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3.12.2025 г., 22:09 ч. UTC

Придобивния, сливания и поглъщания

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

3.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

3.12.2025 г., 21:49 ч. UTC

Печалби

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3.12.2025 г., 21:23 ч. UTC

Печалби

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3.12.2025 г., 21:19 ч. UTC

Печалби

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3.12.2025 г., 21:06 ч. UTC

Печалби

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3.12.2025 г., 21:04 ч. UTC

Печалби

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3.12.2025 г., 21:04 ч. UTC

Печалби

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3.12.2025 г., 21:03 ч. UTC

Печалби

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Сравнение с други в отрасъла

Ценова промяна

Recursion Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

83.49% нагоре

12-месечна прогноза

Среден 8 USD 83.49%

Висок 8 USD

Нисък 8 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Recursion Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Recursion Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

4.15 / 4.75Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

167 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.